Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07SKJ
|
|||
| Former ID |
DIB013856
|
|||
| Drug Name |
LY3015014
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99] | Phase 2 | [1] | |
| Company |
Eli lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Target Info | . | [2] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01890967) A Study of LY3015014 in Participants With High Cholesterol. U.S. National Institutes of Health. | |||
| REF 2 | The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.